| 前收市價 | 2.3200 |
| 開市 | 1.5500 |
| 買盤 | 2.3000 |
| 賣出價 | 2.5800 |
| 拍板 | 62.50 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 1.5500 - 2.1300 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 267 |
ZacksGilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Motley Fool2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years
These companies have grown their dividends despite some troubles.
InvestorPlace3 Biotech Stocks to Buy Now: May 2024
While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, such as the COVID-19 pandemic bringing the value of biotechnology to the forefront or even the expansion of education in the biosciences, the fact remains – biotech is getting more attention than ever before. Nowadays, both institutional and retail investors are discussing which are the best biotech st
